PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.14%
Revenue growth at 75-90% of ADI's 2.57%. Bill Ackman would push for innovation or market expansion to catch up.
12.09%
Gross profit growth above 1.5x ADI's 4.33%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
128.36%
EBIT growth above 1.5x ADI's 77.90%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
128.36%
Operating income growth above 1.5x ADI's 77.90%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
119.86%
Net income growth above 1.5x ADI's 72.54%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
119.44%
EPS growth above 1.5x ADI's 77.08%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
119.44%
Diluted EPS growth above 1.5x ADI's 73.91%. David Dodd would see if there's a robust moat protecting these shareholder gains.
2.54%
Share change of 2.54% while ADI is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
2.54%
Diluted share change of 2.54% while ADI is zero. Bruce Berkowitz might see a minor difference that could widen over time.
0.23%
Dividend growth of 0.23% while ADI is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.
-73.66%
Negative OCF growth while ADI is at 134.62%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-87.40%
Negative FCF growth while ADI is at 212.13%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
1.63%
10Y revenue/share CAGR under 50% of ADI's 129.70%. Michael Burry would suspect a lasting competitive disadvantage.
-6.45%
Negative 5Y CAGR while ADI stands at 24.55%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-22.48%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
64.62%
10Y OCF/share CAGR under 50% of ADI's 866.16%. Michael Burry would worry about a persistent underperformance in cash creation.
506.54%
5Y OCF/share CAGR above 1.5x ADI's 27.76%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-52.39%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
26.17%
Below 50% of ADI's 450.68%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
892.78%
5Y net income/share CAGR above 1.5x ADI's 19.34%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-72.86%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
363.72%
10Y equity/share CAGR at 75-90% of ADI's 474.91%. Bill Ackman would push for either higher ROE or more earnings retention to catch the competitor.
67.55%
5Y equity/share CAGR at 50-75% of ADI's 131.07%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-6.45%
Negative 3Y equity/share growth while ADI is at 63.79%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
46.91%
Dividend/share CAGR of 46.91% while ADI is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
4.65%
Dividend/share CAGR of 4.65% while ADI is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
3.23%
3Y dividend/share CAGR of 3.23% while ADI is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
12.16%
AR growth well above ADI's 1.35%. Michael Burry fears inflated revenue or higher default risk in the near future.
11.65%
We show growth while ADI is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-1.93%
Negative asset growth while ADI invests at 1.05%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.52%
We have a declining book value while ADI shows 2.52%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-20.32%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-0.97%
Our R&D shrinks while ADI invests at 0.01%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
4.51%
SG&A growth well above ADI's 0.16%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.